Top Page
Marvel Biosciences Corp
(MRVL)
Marvel Biosciences Corp (MRVL) vs. S&P 500 (SPY)
Marvel Biosciences Corp Business Overview & Revenue Model
Marvel Biosciences Corp Financial Statement Overview
| Breakdown | ||||
| Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -887.52K | -1.38M | -613.10K | -265.20K | EBIT |
| ― | -2.32M | -2.54M | 806.33K | -954.20K | EBITDA |
| 0.00 | -2.25M | -2.51M | -1.25M | -1.02M | Net Income Common Stockholders |
| ― | -2.29M | -2.55M | -3.04M | -955.66K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 345.77K | 556.62K | 593.21K | 2.39M | 224.81K | Total Assets |
| 491.31K | 672.39K | 913.54K | 2.47M | 295.99K | Total Debt |
| 1.71M | 1.00M | 0.00 | 0.00 | 0.00 | Net Debt |
| 1.36M | 443.38K | -593.21K | -2.39M | -224.81K | Total Liabilities |
| 3.32M | 2.39M | 718.00K | 112.48K | 177.18K | Stockholders Equity |
| -2.83M | -1.72M | 195.54K | 2.36M | 118.80K |
| Cash Flow | Free Cash Flow | |||
| -1.18M | -1.33M | -2.19M | -1.37M | -538.53K | Operating Cash Flow |
| -1.18M | -1.33M | -2.19M | -1.37M | -538.53K | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 381.57K | 0.00 | Financing Cash Flow |
| 968.64K | 1.30M | 394.00K | 3.16M | 763.17K |
Marvel Biosciences Corp Technical Analysis
Marvel Biosciences Corp Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.36B | 3.81 | -42.57% | 2.86% | 17.10% | 1.33% | |
50 Neutral | C$4.16M | ― | -160.58% | ― | 44.96% | -827.30% | |
44 Neutral | C$4.86M | ― | -62.10% | ― | -60.08% | 43.19% | |
43 Neutral | $260.78M | ― | -54.98% | ― | 92.38% | 12.79% | |
22 Underperform | C$3.81M | ― | 45.74% | ― | ― | ― |
Marvel Biosciences Corp Corporate Events
Marvel Biosciences Corp. announced the closing of the second tranche of its non-brokered private placement, issuing 150,000 units for gross proceeds of $18,750. The proceeds will be used for drug formulation, toxicology studies, and general working capital. The company also corrected a previous error regarding finders’ fees and announced the termination of a separate private placement. This development could enhance Marvel’s financial position, enabling further research and development in its pharmaceutical pursuits.
Spark’s Take on TSE:MRVL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MRVL is a Underperform.
Marvel Biosciences Corp’s stock score of 38.5 reflects significant financial difficulties, including no revenue and high leverage. While technical indicators are bearish and valuation remains poor, recent corporate events like promising research results and successful funding initiatives provide a positive outlook for future potential, slightly offsetting the fundamentally weak financial and technical situation.
To see Spark’s full report on TSE:MRVL stock, click here.
Marvel Biosciences Corp. announced promising results from its preclinical study on Rett syndrome, where its lead compound MB-204 significantly outperformed Trofinetide, the only FDA and Health Canada approved treatment for the condition. The study demonstrated that MB-204 maintained its effectiveness even after treatment cessation, showing a sustained carry-over effect, which suggests its potential as a novel treatment for Rett syndrome and possibly other neurological disorders. The company plans to present these findings at the International Rett Syndrome Foundation Scientific Meeting, indicating a positive step towards advancing MB-204’s therapeutic applications.
Spark’s Take on TSE:MRVL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MRVL is a Underperform.
Marvel Biosciences Corp’s stock score of 38 highlights significant financial challenges, including no revenue and high leverage. While technical indicators are bearish, recent corporate events like funding and promising research offer a glimmer of hope, slightly offsetting the fundamentally weak financial and technical situation.
To see Spark’s full report on TSE:MRVL stock, click here.
Marvel Biosciences Corp. announced that it will present its recent preclinical studies of MB-204 at the International Rett Syndrome Foundation Scientific Meeting in June 2025. This presentation, led by Chief Science Officer Dr. Mark Williams and research collaborators from the iBraiN Institute, will highlight promising data in treating Rett Syndrome and Autism Spectrum Disorder. The company is also preparing to apply for Orphan Drug Designation for MB-204 with the U.S. FDA, aiming to advance its development towards clinical trials. This participation underscores Marvel’s commitment to addressing unmet needs in neurological and neurodevelopmental disorders, potentially strengthening its industry position and fostering new collaborations.
Spark’s Take on TSE:MRVL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MRVL is a Underperform.
Marvel Biosciences Corp is facing severe financial difficulties, with no revenue, high leverage, and dependency on external funding. The bearish technical indicators and poor valuation further stress the company’s challenges. However, recent corporate events surrounding funding and product development provide a glimmer of hope for future potential, slightly offsetting the fundamentally weak financial and technical situation.
To see Spark’s full report on TSE:MRVL stock, click here.
Marvel Biosciences Corp. has been invited to present its latest research findings at the Alzheimer’s Association International Conference in July 2025. The company will showcase preclinical data from its acute Alzheimer’s disease study, highlighting MB-204’s potential as a disease-modifying therapy by significantly reducing tau hyperphosphorylation in mice. This presentation underscores Marvel’s commitment to advancing Alzheimer’s research and could enhance its positioning in the biotechnology industry. Additionally, Marvel is conducting a chronic Alzheimer’s disease study with results expected in Q3 2025, supported by Alberta Innovates.
Spark’s Take on TSE:MRVL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MRVL is a Underperform.
Marvel Biosciences Corp faces severe financial difficulties with no revenue, high leverage, and dependency on external funding. The stock is in a bearish technical position, and valuation is poor due to negative earnings. However, recent corporate events surrounding funding and product development offer some positive outlook for future potential, slightly offsetting the fundamentally weak financial and technical situation.
To see Spark’s full report on TSE:MRVL stock, click here.
Marvel Biosciences Corp. has announced the closing of the first tranche of a non-brokered private placement, raising $1,000,000 through the issuance of 8,000,000 units. Each unit consists of one common share and one warrant, with the proceeds intended for drug formulation, toxicology studies, and general working capital. The offering, which is subject to TSX Venture Exchange approval, is aimed at accredited investors and includes a finder’s fee arrangement. The announcement signifies Marvel’s ongoing efforts to secure funding for its pharmaceutical development initiatives, potentially enhancing its market position in the biotechnology industry.
Marvel Biosciences Corp. announced its intention to file for Orphan Drug Designation with the U.S. FDA for MB-204 as a treatment for Rett Syndrome, following promising preclinical results. This designation could accelerate MB-204’s development and strengthen Marvel’s position in rare neurological therapies, offering potential benefits such as market exclusivity and expedited regulatory processes.
Marvel Biosciences Corp announced promising results from a preclinical study of its lead compound MB-204 for Rett syndrome, conducted with the iBraiN Institute. MB-204 significantly outperformed the currently approved treatment, Trofinetide, in reversing social and behavioral deficiencies in Mecp2 mice, suggesting it could be a promising treatment for Rett Syndrome. The company plans to publish and present the data at a scientific conference.
Marvel Biosciences Corp. announced its participation in the Bloom Burton & Co. Healthcare Investor Conference in May 2025, where its executives will present and engage with investors. This opportunity allows Marvel to showcase its innovative drug redevelopment approach and strengthen its connections within the healthcare investment community, potentially enhancing its industry positioning and attracting investor interest.